文献速递产科

2008至2013年美国住院产后长效可逆避孕与绝育的使用情况

Inpatient Postpartum Long-Acting Reversible Contraception and Sterilization in the United States, 2008-2013.
PubMed 文献 · Obstet Gynecol · 2017-01-01

该回顾性队列研究利用2008至2013年全国住院患者样本,分析分娩住院期间宫内节育器、避孕植入剂和输卵管绝育的使用率及相关因素。长效可逆避孕插入率从每万次分娩1.86升至13.5(P<.001),输卵管绝育保持稳定(每万次分娩711至683,P=.24)。

要点

  • 长效可逆避孕插入率从2008至2009年的每万次分娩1.86升至2012至2013年的13.5(P<.001)。
  • 输卵管绝育率保持稳定,每万次分娩711至683(P=.24)。
  • 校正后,长效可逆避孕使用在城市教学医院最高(校正OR 20.85,95%CI 12.73-34.15)。

核心结论

  • 长效可逆避孕插入率从每万次分娩1.86升至13.5,但仍不足绝育率的2%。
  • 住院产后长效可逆避孕插入更常见于病情更重、经济更差且在城市教学医院分娩的女性。

研究设计与样本

  • 回顾性队列研究,使用2008至2013年全国住院患者样本(全支付方数据库)。
  • 样本包括4,691,683例出院记录,代表22,667,204次分娩住院。
  • 通过ICD-9-CM编码识别宫内节育器插入、避孕植入剂插入和输卵管绝育。
  • 采用加权多变量logistic回归分析预测因素与长效可逆避孕及绝育的可能性。

主要发现

  • 长效可逆避孕插入率从2008至2009年的每万次分娩1.86升至2012至2013年的13.5(P<.001)。
  • 输卵管绝育率保持稳定,每万次分娩711至683(P=.24)。
  • 校正所有预测因素后,与既无长效可逆避孕也无绝育相比,有内科合并症的女性长效可逆避孕使用率最高(每万次分娩15.04,标准误2.11,校正OR 1.92,95%CI 1.72-2.13)。
  • 非私人保险者长效可逆避孕使用率较高(每万次分娩13.50,标准误2.14,校正OR 5.23,95%CI 3.82-7.16);城市教学医院最高(每万次分娩14.92,标准误2.25,校正OR 20.85,95%CI 12.73-34.15)。
  • 绝育在24岁及以下女性中可能性最低(每万次分娩251.04,标准误4.88,校正OR 0.12,95%CI 0.12-0.13,与35岁及以上相比),剖宫产时最高(每万次分娩1,568.74,标准误20.81,校正OR 6.25,95%CI 5.88-6.63)。

关键数值与推荐

  • 仅比较长效可逆避孕与绝育使用者时,长效可逆避孕使用者更多为非私人保险(84.95% vs 57.17%,校正OR 1.90,95%CI 1.38-2.63)。
  • 长效可逆避孕使用者更多在城市教学医院分娩(94.65% vs 45.47%,校正OR 38.39,95%CI 23.52-62.64)。
  • 长效可逆避孕使用者更多在较晚研究年份分娩(2012至2013年55.72% vs 32.18%,校正OR 8.26,95%CI 4.42-15.44,与2008至2009年相比)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To measure rates of long-acting reversible contraception (LARC), including intrauterine devices and contraceptive implants, and tubal sterilization during delivery hospitalizations and correlates of their use. METHODS: This retrospective cohort study used the 2008-2013 National Inpatient Sample, a publicly available all-payer database. We identified delivery hospitalizations with the International Classification of Diseases, 9th Revision, Clinical Modification codes for intrauterine device insertion, contraceptive implant insertion, and tubal sterilization. We used weighted multivariable logistic regression to examine associations between predictors (age, delivery mode, medical comorbidity, payer, hospital type, geographic region, and year) and likelihood of LARC and sterilization and to compare characteristics of LARC and sterilization users. RESULTS: Our sample included 4,691,683 discharges, representing 22,667,204 delivery hospitalizations. Long-acting reversible contraception insertion increased from 1.86 per 10,000 deliveries (2008-2009) to 13.5 per 10,000 deliveries (2012-2013; P<.001); tubal sterilization remained stable (711-683 per 10,000 deliveries; P=.24). In multivariable analysis adjusting for all predictors, compared with neither LARC nor sterilization, LARC use was highest among women with medical comorbidities (count per 10,000 deliveries: 15.04, standard error 2.11, adjusted odds ratio [OR] 1.92, 95% confidence interval [CI] 1.72-2.13), nonprivate payer (13.50, standard error 2.14, adjusted OR 5.23, 95% CI 3.82-7.16), and at urban teaching hospitals (14.92, standard error 2.25, adjusted OR 20.85, 95% CI 12.73-34.15). Sterilization was least likely among women aged 24 years or younger (251.04, standard error 4.88, adjusted OR 0.12 95% CI 0.12-0.13, compared with 35 years or older) and most likely with cesarean delivery (1,568.74, standard error 20.81, adjusted OR 6.25, 95% CI 5.88-6.63). Comparing only LARC and sterilization users, LARC users tended to have nonprivate insurance (84.95% compared with 57.17%, adjusted OR 1.90, 95% CI 1.38-2.63) and deliver at urban teaching hospitals (94.65% compared with 45.47%, adjusted OR 38.39, 23.52-62.64) in later study years (2012-2013; 55.72% compared with 32.18%, adjusted OR 8.26, 95% CI 4.42-15.44, compared with 2008-2009). CONCLUSION: Long-acting reversible contraception insertion increased from 1.86 to 13.5 per 10,000 deliveries but remained less than 2% of the sterilization rate. Inpatient postpartum LARC insertion is more likely among sicker, poorer women delivering at urban teaching hospitals.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Moniz MH, Chang T, Heisler M, et al. Inpatient Postpartum Long-Acting Reversible Contraception and Sterilization in the United States, 2008-2013. Obstet Gynecol. 2017. PMID: 28486357. doi:10.1097/AOG.0000000000001970

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。